Practice Points
Molecular diagnostics and NGS in the clinic: where are we and where do we need to go?
The development of next generation sequencing (NGS) has been a game changer for our understanding of genetics, and in turn for many aspects of biomedicine. This includes cancer, where it has led to greater understanding of the genetic changes that…
Covid-19 pandemic: information and resources to support the cancer care community
As soon as the first analysis of the risk for severe COVID-19 in patients with cancer was published online in Lancet Oncology on February 14th, 2020, it emerged that these patients might have a higher risk of COVID-19 compared to…
Delivering the best cancer care during the pandemic
Key messages from the e-ESO faculty [caption id="attachment_9782" align="aligncenter" width="1440"] e-ESO coordinator Marco Siano, chief physician at the Interdisciplinary Cancer Service, HRC Hopital Riviera-Chablais Rennaz, Switzerland (left); ESO deputy scientific director Alex Eniu, medical oncologist and head of the breast…
Tackling resistance to anti-EGFR therapies, from challenges to re-challenge
Since their first approval and use, more than 15 years ago, inhibitors of the Epidermal Growth Factor Receptor (EGFRi) have revolutionized the clinical practice and the prognosis for cancer patients, especially those diagnosed with colorectal (CRC) and lung cancer. These…